Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. We show 8 historical shares outstanding datapoints in our ELVN shares outstanding history coverage, used to compute ELVN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ELVN market cap history over the course of time is important for investors
interested in comparing ELVN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ELVN versus a peer is one thing; comparing
ELVN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ELVN can fluctuate over the course of history.
With this page we aim to empower investors researching ELVN by allowing them to research the ELVN market cap history. |
Free ELVN Email Alerts:
Video: The Importance of Market Cap
